Asia-Pacific Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Country (Turkey), Market Trends and Forecast to 2026
Market Analysis and Insights: Europe Exosome Therapeutic Market
Exosome therapeutic market is expected to gain market growth in the forecast period of 2020 to 2026. Data Bridge Market Research analyses that the market is growing with highest CAGR of 24.6% in the forecast period of 2019 to 2026 and expected to reach USD 5,770.87 million by 2026 from USD 994.50 million in 2019. Increasing demand for anti-aging therapies is the factors for the market growth.
Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.
Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving patent grant for clinical trial for exosome therapeutic. For instance, In August, evox Therapeutics has received patents granted by the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) for three key patents which includes exosome-mediated RNA therapeutics and targeted exosome drug delivery. This patent grant will help the company to safe guard its product.
This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Europe Exosome therapeutic Market Scope and Market Size
Europe exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes therapeutics provides better efficiency in treatment of disease compare than hybrid exosomes therapeutics. This factor allows market to grow with highest CAGR in the forecasted period of 2026.
Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells segment is dominating the market because it is most popular stem cell type which used in medicine. It is also proved effectiveness for a various type of disease with fewer side effects. Exosome Therapeutics (HEVs) is expected to grow with highest CAGR for forecasted of 2026.
Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because first line treatment for cancers as well as slow down the growth of cancer cells.
Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules is dominating in the market because its long blood circulation time and targeting ability, better stability, safety and ease of manufacture compare than small molecules.
Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology is dominating in the market because increasing incidence of cancers in the Europe. As per the European Journal of Cancer, in 2018, around 25.00% population suffered from cancers in the Europe.
Based on route of administration, the market is segmented into oral and parenteral. Parenteral route of administration segment is dominating in the market because it is provide immediate effect compare than oral route of administration as well as less dose errors.
The Europe exosome therapeutic market is also segmented on the basis of end user. The Exosome Therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes and others. Hospitals segment is dominating in the market because hospitals provide better treatment facilities as well as advance treatment technology available in the market. In 2017, around 497,200 hospitals recorded in Germany.
Exosome therapeutic Market Country Level Analysis
The Europe market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.
The countries covered in the exosome therapeutics market report are Turkey in Europe.
Europe exosome therapeutic market is growing due to high demand of exosome therapeutics form healthcare professionals to use exosome therapeutics as anti-aging therapy’s therefore exosome therapeutics is expected to grow at the significant growth rate in the forecast period of 2019 to 2026 because of increasing aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, and regulatory scenario and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
High Amount of Investment in Exosome Therapeutics by Investors to Develop New Technologies in Exosome Therapeutic Market
Europe exosome therapeutic market also provides you with detailed market analysis for every country growth in installed base of different kind of products for exosome therapeutics market, impact of technology using life line curves and changes in automobile regulatory scenarios and their impact on the exosome therapeutics market. The data is available for historic period 2010 to 2017.
Competitive Landscape and Exosome Therapeutic Market Share Analysis
Europe exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Europe exosome therapeutics market.
The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, United Therapeutics Corporation, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Group among other players domestic and global. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
- In July 2019, ReNeuron Group plc has received patent grant for exosome technology platform in Korea (KR 10-1993027), China (CN 104321062 B and CN 104703609 B), Japan (JP 6450673) and Europe (EP2833893 and EP2877187) which includes claims to methods of production, a method of producing exosomes derived from differentiated stem cells, and composition of matter for exosomes derived from the Company's CTX neural stem cells. Furthermore, the company has received patent grant in Japan (JP 6491661) with claim rights of a neural stem cell exosome in the treatment of glioma (brain cancer). The patent grants will help the company to form collaboration in order to explore exosome platform as a novel system for delivering advanced therapeutics.
- In January 2019, Jazz Pharmaceuticals, Inc. has collaborated with Codiak BioSciences to develop and commercialize exosome therapeutics to treat cancer. The collaboration will help the company to address issues which have been often implicated in solid tumours and hematological malignancies.
Such investment and partnership other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.
Customization Available: Europe Exosome Therapeutics Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.